CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
Zenith Epigenetics has commenced a Phase IIb clinical trial of a combination of its ZEN-3694 with Pfizer’s Talzenna (talazoparib) to treat patients with triple-negative breast cancer (TNBC).
CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical...
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer. The trial will be conducted by NCI funded investigators and will evaluate the safety and activity of this combination in patients with solid tumors that have become resistant to other therapies. This Phase 1/1b clinical trial will also evaluate a triple combination of ZEN-3694 + OPDIVO + YERVOY (an inhibitor of another immune checkpoints, CTLA4). Upon determination of a dosing regimen of the aforementioned double and triple combination, the trial will be expanded to ovarian cancer patients who have progressed on platinum-based chemotherapy.
CALGARY, Alberta, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces a publication in the high-impact Nature Publishing Group journal of Cancer Gene Therapy, titled: “Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.”
CALGARY, Alberta, June 24, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage pharmaceutical company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal.
CALGARY, Alberta, April 22, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces it has entered into an agreement with Astellas Pharma Inc. (“Astellas”) to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide), in patients with metastatic castration resistant prostate cancer (mCRPC).
CALGARY, Alberta, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate the combination of Zenith’s epigenetic therapy – BET inhibitor ZEN-3694 – with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.
CALGARY, Alberta, July 29, 2020 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today significant clinical advances of ZEN-3694, the Company’s lead therapeutic compound being developed for epigenetic combination therapies in multiple oncology indications.